Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update describing the safety/tolerability study of SX-682 with nivolumab as maintenance therapy for metastatic pancreatic ductal adenoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• OPDIVO (nivolumab)
• SX-682

Snippet

Sponsor: University of Rochester | Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 1 | Status: RECRUITING